Cargando…
A network representation approach for COVID-19 drug recommendation
The coronavirus disease 2019 (COVID-19) has outbreak since early December 2019, and COVID-19 has caused over 100 million cases and 2 million deaths around the world. After one year of the COVID-19 outbreak, there is no certain and approve medicine against it. Drug repositioning has become one line o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458160/ https://www.ncbi.nlm.nih.gov/pubmed/34562584 http://dx.doi.org/10.1016/j.ymeth.2021.09.009 |
_version_ | 1784571252778729472 |
---|---|
author | Liu, Haifeng Lin, Hongfei Shen, Chen Yang, Liang Lin, Yuan Xu, Bo Yang, Zhihao Wang, Jian Sun, Yuanyuan |
author_facet | Liu, Haifeng Lin, Hongfei Shen, Chen Yang, Liang Lin, Yuan Xu, Bo Yang, Zhihao Wang, Jian Sun, Yuanyuan |
author_sort | Liu, Haifeng |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) has outbreak since early December 2019, and COVID-19 has caused over 100 million cases and 2 million deaths around the world. After one year of the COVID-19 outbreak, there is no certain and approve medicine against it. Drug repositioning has become one line of scientific research that is being pursued to develop an effective drug. However, due to the lack of COVID-19 data, there is still no specific drug repositioning targeting the COVID-19. In this paper, we propose a framework for COVID-19 drug repositioning. This framework has several advantages that can be exploited: one is that a local graph aggregating representation is used across a heterogeneous network to address the data sparsity problem; another is the multi-hop neighbors of the heterogeneous graph are aggregated to recall as many COVID-19 potential drugs as possible. Our experimental results show that our COVDR framework performs significantly better than baseline methods, and the docking simulation verifies that our three potential drugs have the ability to against COVID-19 disease. |
format | Online Article Text |
id | pubmed-8458160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84581602021-09-23 A network representation approach for COVID-19 drug recommendation Liu, Haifeng Lin, Hongfei Shen, Chen Yang, Liang Lin, Yuan Xu, Bo Yang, Zhihao Wang, Jian Sun, Yuanyuan Methods Article The coronavirus disease 2019 (COVID-19) has outbreak since early December 2019, and COVID-19 has caused over 100 million cases and 2 million deaths around the world. After one year of the COVID-19 outbreak, there is no certain and approve medicine against it. Drug repositioning has become one line of scientific research that is being pursued to develop an effective drug. However, due to the lack of COVID-19 data, there is still no specific drug repositioning targeting the COVID-19. In this paper, we propose a framework for COVID-19 drug repositioning. This framework has several advantages that can be exploited: one is that a local graph aggregating representation is used across a heterogeneous network to address the data sparsity problem; another is the multi-hop neighbors of the heterogeneous graph are aggregated to recall as many COVID-19 potential drugs as possible. Our experimental results show that our COVDR framework performs significantly better than baseline methods, and the docking simulation verifies that our three potential drugs have the ability to against COVID-19 disease. Elsevier Inc. 2022-02 2021-09-23 /pmc/articles/PMC8458160/ /pubmed/34562584 http://dx.doi.org/10.1016/j.ymeth.2021.09.009 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Liu, Haifeng Lin, Hongfei Shen, Chen Yang, Liang Lin, Yuan Xu, Bo Yang, Zhihao Wang, Jian Sun, Yuanyuan A network representation approach for COVID-19 drug recommendation |
title | A network representation approach for COVID-19 drug recommendation |
title_full | A network representation approach for COVID-19 drug recommendation |
title_fullStr | A network representation approach for COVID-19 drug recommendation |
title_full_unstemmed | A network representation approach for COVID-19 drug recommendation |
title_short | A network representation approach for COVID-19 drug recommendation |
title_sort | network representation approach for covid-19 drug recommendation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458160/ https://www.ncbi.nlm.nih.gov/pubmed/34562584 http://dx.doi.org/10.1016/j.ymeth.2021.09.009 |
work_keys_str_mv | AT liuhaifeng anetworkrepresentationapproachforcovid19drugrecommendation AT linhongfei anetworkrepresentationapproachforcovid19drugrecommendation AT shenchen anetworkrepresentationapproachforcovid19drugrecommendation AT yangliang anetworkrepresentationapproachforcovid19drugrecommendation AT linyuan anetworkrepresentationapproachforcovid19drugrecommendation AT xubo anetworkrepresentationapproachforcovid19drugrecommendation AT yangzhihao anetworkrepresentationapproachforcovid19drugrecommendation AT wangjian anetworkrepresentationapproachforcovid19drugrecommendation AT sunyuanyuan anetworkrepresentationapproachforcovid19drugrecommendation AT liuhaifeng networkrepresentationapproachforcovid19drugrecommendation AT linhongfei networkrepresentationapproachforcovid19drugrecommendation AT shenchen networkrepresentationapproachforcovid19drugrecommendation AT yangliang networkrepresentationapproachforcovid19drugrecommendation AT linyuan networkrepresentationapproachforcovid19drugrecommendation AT xubo networkrepresentationapproachforcovid19drugrecommendation AT yangzhihao networkrepresentationapproachforcovid19drugrecommendation AT wangjian networkrepresentationapproachforcovid19drugrecommendation AT sunyuanyuan networkrepresentationapproachforcovid19drugrecommendation |